Biomerica's signs five-year distribution agreement with Canadian partner to market new test to detect H. pylori bacteria, called hp+detect.
Biomerica Inc. (Irvine, CA) has signed an exclusive five-year distribution agreement with a Canadian partner to distribute and market Biomerica’s new proprietary Helicobacter pylori test, called hp+detect. The test was developed for the identification and monitoring of H. pylori infection, which is a leading cause of duodenal and gastric ulcers, and a contributing risk factor associated with gastric cancer. The test is to be used by physicians and medical centers to diagnose the presence of H. pylori and monitor the efficacy of treatments.
Utilizing clinical data recently generated by Biomerica, the distribution partner will now seek Health Canada clearance in order to be able to sell the product in the country. Biomerica also intends to seek a CE Mark for the sale of the product in the European Union, and FDA clearance in U.S.
“H. pylori infection can cause serious health conditions, so early detection of the disease in symptomatic patients is important for those infected with these bacteria. Our hp+detect product identifies the presence of H. pylori antigen, enabling doctors to diagnose patients, as well as monitor treatment efficacy. Because of the rise of antibiotic resistance in H. pylori treatment, and the long-term cancer risk associated with proton-pump inhibitor ulcer medication use, it is important to monitor the eradication of infection,” said Zack Irani, chairman and chief executive officer of Biomerica, in a press release. “We’re pleased to enter into this relationship with a well-established medical distributor in Canada. This partnership will be our first step to launching the hp+detect test in markets around the world to assist gastroenterologists and other medical professionals who are dedicated to preventing ulcers and gastric cancer in the patients they treat.”